Soros Fund Management - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Soros Fund Management ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$20,801,000
+6.1%
32,298,0000.0%0.39%
+5.4%
Q4 2020$19,611,000
+44.8%
32,298,000
+65.2%
0.37%
+11.4%
Q3 2020$13,548,00019,552,0000.33%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 18,590,000$11,232,0000.16%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 5,175,000$3,118,0000.07%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$136,0000.02%
Calamos Advisors LLC 5,000,000$3,012,0000.01%
FRANKLIN RESOURCES INC 21,000,000$12,846,0000.01%
FMR LLC 17,435,000$10,534,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
MORGAN STANLEY 4,426,000$2,545,0000.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders